Merck inks $200 million deal for Hengrui's midstage heart disease drug
Hengrui Pharma has granted Merck exclusive rights to develop, manufacture and commercialize HRS-5346 worldwide, excluding Greater China region
Hengrui Pharma has granted Merck exclusive rights to develop, manufacture and commercialize HRS-5346 worldwide, excluding Greater China region
Adults taking Mounjaro with diet and exercise in a controlled clinical trial lost on average 21.8 kg at the highest dose (15mg) and 15.4 kg at the lowest dose (5mg)
The inspection, conducted from March 17 to March 21, 2025, concluded with one observation in Form 483
This facility represents a significant step in Croda’s Pharma business strategy to ‘Empower biologics delivery’
TB treatment coverage in India increased by 32% in the last eight years from 53% in 2015 to 85% in 2023
This program aims to develop a fully human monoclonal antibody against a novel immune checkpoint protein that enables T cell activation
The product is being recalled because the infusion bag is incorrectly labeled as Levetiracetam in 0.82% Sodium Chloride Injection 500 mg/100 mL single-dose bag, while the aluminum overwrap packaging correctly identifies the product as Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 m
Overall investment in the US facility is estimated around US$50 million
403 entries from 22 states covering 168 districts highlight groundbreaking initiatives vital to improving national nutrition metrics.
This addition strengthens Dr. Agarwals Eye Hospital's vast network of 28 hospitals across Karnataka and 220+ facilities worldwide
Subscribe To Our Newsletter & Stay Updated